Search

Displaying results 1201 - 1210 of 10000 in total
  1. Drug

    Desvenlafaxine

    go.drugbank.com/drugs/DB06700
    ApprovedInvestigational

    [L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine].

    Synonyms: O-desmethylvenlafaxineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    Cepeginterferon alfa-2B

    go.drugbank.com/drugs/DB12814
    Investigational

    Cepeginterferon alfa-2B is under investigation in clinical trial NCT01889433 (An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic … Hepatitis C).

    Synonyms: Cepeginterferon Alfa 2 B, Pegylated human interferon A-2BCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  3. Drug

    Glimepiride

    go.drugbank.com/drugs/DB00222
    ApprovedInvestigational

    It is sometimes classified as a third-generation SU because it has larger substitutions than other second-generation SUs. … Compared to [glipizide], another second SU drug, glimepiride has a longer duration of action.

    Mixtures: AMARYL® M SR, AMARYL® M SRCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  4. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.

    Synonyms: T-DXd, T- DXdCategories: MATE 2 Substrates, P-glycoprotein substrates
  5. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). … Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein substratesProducts: BESPONSA 1 MG IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 1 ADET
  6. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

  7. Drug

    Evalstotug

    go.drugbank.com/drugs/DB19410
    Investigational

    Evalstotug is under investigation in clinical trial NCT05271604 (A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck).

    Synonyms: Immunoglobulin G1-kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody, Immunoglobulin G1 [de-448-lysine], anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal BA3071 γ1-chain), disulfide with human monoclonal BA3071 κ-chain, dimer
  8. Pathway

    Intracellular Signalling Through Adenosine Receptor A2a and Adenosine

    smpdb.ca/view/SMP0000320
    Signaling

    The adenosine receptor A2a activates G(s) proteins which lead to the activation of adenylyl cyclase which produces the secondary messenger cAMP. cAMP activates PKA (protein kinase A) which phosphorylates

    Drugs: ATP · Adenosine · Magnesium cation · Zinc · Cyclic adenosine monophosphate · Pyrophosphoric acid
    Enzymes: Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12, Guanine nucleotide-binding protein G(s) subunit alpha isoforms short
  9. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    It is not pathogenic and it causes a very mild immune response. … Voretigene Neparvovec-rzyl (VN-rzyl) is an adeno-associated virus vector-based gene therapy.[L1094] An adeno-associated virus is a small virus that infects humans and other primates.

  10. Drug

    Aspartyl-alanyl-diketopiperazine

    go.drugbank.com/drugs/DB14940
    Investigational

    Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).